|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-9-26
|
|
pubmed:abstractText |
The biologic effects of neoadjuvant tumor therapies on the immune system of cancer patients are largely unknown. Immune deviations may be particularly detrimental if they occur in conjunction with postoperative immunosuppression. The effects of combined radiochemotherapy (RCTx) on T cell functions in patients with squamous cell carcinoma of the esophagus were investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0039-6060
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
495-501
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12324764-Adult,
pubmed-meshheading:12324764-Aged,
pubmed-meshheading:12324764-Combined Modality Therapy,
pubmed-meshheading:12324764-Cytokines,
pubmed-meshheading:12324764-Esophageal Neoplasms,
pubmed-meshheading:12324764-Female,
pubmed-meshheading:12324764-Histocompatibility Antigens Class II,
pubmed-meshheading:12324764-Humans,
pubmed-meshheading:12324764-Immune Tolerance,
pubmed-meshheading:12324764-Lymphocyte Activation,
pubmed-meshheading:12324764-Male,
pubmed-meshheading:12324764-Middle Aged,
pubmed-meshheading:12324764-Neoadjuvant Therapy,
pubmed-meshheading:12324764-T-Lymphocytes
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy.
|
|
pubmed:affiliation |
Department of Surgery, Technische Universität München, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
